Zydus Cadila: USFDA gives approval for potassium chloride capsules

Zydus Cadila has received the final approval from USFDA for marketing Potassium Chloride Extended-Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg). This will be manufactured at the company’s formulations manufacturing facility at SEZ, Ahmedabad.

This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. Potassium helps the cells, kidneys, heart, muscles and nerves to work properly. Some conditions that can lower the body's potassium level include severe prolonged diarrhoea and vomiting, hormone problems such as hyperaldosteronism or treatment with diuretics i.e. water pills.

Earlier, it also received final approval from USFDA for marketing Atenolol and Chlorthalidone Tablets USP, 50 mg/25 mg and 100 mg/25 mg.

This medication is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. Atenolol works by blocking the action of certain natural chemicals in the body, such as epinephrine on the heart and blood vessels. This effect lowers the heart rate, blood pressure and strain on the heart. Chlorthalidone is a diuretic and causes the body to get rid of extra salt and water. It also helps to relax the blood vessels so that blood can flow easily.

The group now has 254 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY04.

Cadila Healthcare recorded 52-week high of Rs. 432.40 in September 2018 and since then it has corrected by ~29 per cent and 52-week low of Rs. 306.35 in February 2019.